RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 63 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 63

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Cancer Hospital of Xinjiang Medical University新疆医科大学附属肿瘤医院UrumqiHospital page
  2. Study siteAffiliated Hospital of Guangdong Medical University广东医科大学附属医院ZhanjiangHospital page
  3. Study siteAffiliated Hospital of Guilin Medical University桂林医学院附属医院GuilinHospital page
  4. Study siteAffiliated Hospital of Hebei University河北大学附属医院ShijiazhuangHospital page
  5. Study siteAffiliated Hospital of Xuzhou Medical University徐州医科大学附属医院XuzhouHospital page
  6. Study siteAffiliated Wuxi People's Hospital of Nanjing Medical University无锡市人民医院WuxiHospital page
  7. Study siteAnyang Tumor Hospital安阳市肿瘤医院AnyangHospital page
  8. Study siteBeijing Chest Hospital首都医科大学附属北京胸科医院BeijingHospital page
  9. Study siteChinese PLA General Hospital中国人民解放军总医院BeijingHospital page
  10. Study siteChongqing University Cancer Hospital重庆大学附属肿瘤医院ChongqingHospital page
  11. Study siteChongqing University Three Gorges Hospital重庆大学附属三峡医院ChongqingHospital page
  12. Study siteFirst Affiliated Hospital of Fujian Medical University福建医科大学附属第一医院FuzhouHospital page
  13. Study siteFirst Affiliated Hospital of Guangxi Medical University广西医科大学第一附属医院NanningHospital page
  14. Study siteFirst Affiliated Hospital of Henan University of Science and Technology河南科技大学第一附属医院LuoyangHospital page
  15. Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
  16. Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
  17. Study siteFirst Affiliated Hospital of Wenzhou Medical University温州医科大学附属第一医院WenzhouHospital page
  18. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  19. Study siteFirst Affiliated Hospital of Xiamen University厦门大学附属第一医院XiamenHospital page
  20. Study siteFirst Affiliated Hospital of Xinxiang Medical University河南医药大学第一附属医院XinxiangHospital page
  21. Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
  22. Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
  23. Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
  24. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  25. Study siteFujian Medical University Union Hospital福建医科大学附属协和医院FuzhouHospital page
  26. Study siteHainan General Hospital / Hainan Medical University hospitals海南医学院附属医院/海南省人民医院HaikouHospital page
  27. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  28. Study siteHenan Provincial People's Hospital河南省人民医院ZhengzhouHospital page
  29. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  30. Study siteJiangsu Cancer Hospital江苏省肿瘤医院NanjingHospital page
  31. Study siteJiangxi Cancer Hospital江西省肿瘤医院NanchangHospital page
  32. Study siteJiangxi Provincial People's Hospital江西省人民医院NanchangHospital page
  33. Study siteJilin Cancer Hospital吉林省肿瘤医院ChangchunHospital page
  34. Study siteLanzhou University Second Hospital兰州大学第二医院LanzhouHospital page
  35. Study siteNantong Tumor Hospital南通市肿瘤医院NantongHospital page
  36. Study siteNational Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page
  37. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  38. Study sitePeking University Third Hospital北京大学第三医院BeijingHospital page
  39. Study siteRuijin Hospital上海交通大学医学院附属瑞金医院ShanghaiHospital page
  40. Study siteSecond Affiliated Hospital of Chongqing Medical University重庆医科大学附属第二医院ChongqingHospital page
  41. Study siteSecond Affiliated Hospital of Harbin Medical University哈尔滨医科大学附属第二医院HarbinHospital page
  42. Study siteSecond Affiliated Hospital of Shandong First Medical University山东第一医科大学第二附属医院JinanHospital page
  43. Study siteSecond Affiliated Hospital of Zunyi Medical University遵义医科大学第二附属医院ZunyiHospital page
  44. Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
  45. Study siteSecond Xiangya Hospital中南大学湘雅二医院ChangshaHospital page
  46. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  47. Study siteShanghai Chest Hospital上海市胸科医院ShanghaiHospital page
  48. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  49. Study siteShengjing Hospital of China Medical University中国医科大学附属盛京医院ShenyangHospital page
  50. Study siteSichuan Provincial People's Hospital四川省人民医院ChengduHospital page
  51. Study siteSouthwest Hospital, Army Medical University陆军军医大学第一附属医院(西南医院)ChongqingHospital page
  52. Study siteSun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院GuangzhouHospital page
  53. Study siteTangdu Hospital空军军医大学唐都医院Xi'anHospital page
  54. Study siteThird Affiliated Hospital of Soochow University常州市第一人民医院ChangzhouHospital page
  55. Study siteThird Xiangya Hospital中南大学湘雅三医院ChangshaHospital page
  56. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  57. Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
  58. Study siteWeifang People's Hospital潍坊市人民医院WeifangHospital page
  59. Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
  60. Study siteXuanwu Hospital首都医科大学宣武医院BeijingHospital page
  61. Study siteXuzhou Central Hospital徐州市中心医院XuzhouHospital page
  62. Study siteYunnan Cancer Hospital云南省肿瘤医院KunmingHospital page
  63. Study siteZhongnan Hospital of Wuhan University武汉大学中南医院WuhanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06300177, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Pathologically confirmed locally advanced, unresectable and / or metastatic non-small cell lung cancer (stage III b / III c / IV of american joint committee on cancer (AJCC) 8th);

    Inclusion criterion 3

  3. Disease progression or toxicity after previous treatment with first-line anti-PD-1 / PD-L1 and platinum-containing chemotherapy is not tolerated.Subjects who have clear medical reasons and can not tolerate anti-PD-1 / PD-L1 therapy or platinum-containing chemotherapy;

    Inclusion criterion 5

    History of interstitial lung disease, radiation pneumonitis, and immune-associated pneumonia previously treated with steroids, Or active non-infectious pneumonia with interstitial lung disease, radiation pneumonia, and immune-related pneumonia during the screening period, Presence of active tuberculosis, pneumoconiosis or grade 2 other type of pneumonia, or pulmonary function tests confirming severely impaired pulmonary function;

    Exclusion criterion 14

  4. Age greater than or equal to 18 years old; male and female; eastern cooperative oncology group performance status (ECOG) score 0-1; expected survival period greater than or equal to 3 months;

    Inclusion criterion 2

  5. Having at least one target lesion according to RECIST 1.1;

    Inclusion criterion 6

  6. Human immunodeficiency virus (HIV) antibody positive, liver cirrhosis or active viral hepatitis;

    Exclusion criterion 20

  7. Female subjects of childbearing age should agree that contraception must be used during the study and within 6 months after the end of the study; the serum pregnancy test is negative within 7 days before study enrollment and must be non-lactating subjects; male subjects should agree that contraception must be used during the study and within 6 months after the end of the study period.

    Inclusion criterion 8

    Pregnant or lactating subjects;

    Exclusion criterion 28

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06300177, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntary participation in the study and sign of written informed consent after full informed consent, willing and able to comply with the study procedures and requirements specified in the protocol;
  • Age greater than or equal to 18 years old; male and female; eastern cooperative oncology group performance status (ECOG) score 0-1; expected survival period greater than or equal to 3 months;
  • Pathologically confirmed locally advanced, unresectable and / or metastatic non-small cell lung cancer (stage III b / III c / IV of american joint committee on cancer (AJCC) 8th);
  • Subjects must provide adequate and qualified tumor tissue specimens (surgical resection samples or puncture / biopsy tissue samples within 2 years prior to screening) for confirmation of the KRAS G12C mutation in the central laboratory;
  • Disease progression or toxicity after previous treatment with first-line anti-PD-1 / PD-L1 and platinum-containing chemotherapy is not tolerated.Subjects who have clear medical reasons and can not tolerate anti-PD-1 / PD-L1 therapy or platinum-containing chemotherapy;
  • Having at least one target lesion according to RECIST 1.1;
  • Good function of the major organs;
  • Female subjects of childbearing age should agree that contraception must be used during the study and within 6 months after the end of the study; the serum pregnancy test is negative within 7 days before study enrollment and must be non-lactating subjects; male subjects should agree that contraception must be used during the study and within 6 months after the end of the study period.

Exclusion Criteria:

  • Treatment with a KRAS G12C mutation inhibitor or docetaxel at any previous time;
  • NSCLC with mutations of other driver genes;
  • Symptomatic or progressive aggravation of central nervous system metastasis or cancerous meningitis. Subjects with a history of brain metastasis may be considered to be selected if they are clinically stable;
  • Patients with a previous history of epilepsy;presence of superior vena cava syndrome;
  • Cardiovascular system meets any condition:
  • New York Heart Association (NYHA) Heart Function Grade II and above congestive heart failure;
  • Severe cardiac arrhythmias requiring medical treatment;
  • Acute myocardial infarction, severe or unstable angina pectoris, coronary or peripheral artery bypass surgery within 6 months prior to enrollment;
  • Left ventricular ejection fraction (LVEF) <50%;
  • QT interval (QTcF) at prolonged;
  • Hypertension that is not effectively controlled;
  • Subjects with stroke or other severe cerebrovascular disease within 6 months before enrollment;
  • History of deep vein thrombosis or any other serious thromboembolism within 3 months prior to enrollment;
  • History of interstitial lung disease, radiation pneumonitis, and immune-associated pneumonia previously treated with steroids, Or active non-infectious pneumonia with interstitial lung disease, radiation pneumonia, and immune-related pneumonia during the screening period, Presence of active tuberculosis, pneumoconiosis or grade 2 other type of pneumonia, or pulmonary function tests confirming severely impaired pulmonary function;
  • Severe bone damage due to tumor bone metastasis may occur at present or after randomization;
  • Active or uncontrolled serious infection (≥grade 2 infection of common toxicity criteria for adverse events (CTC AE)) or fever of unknown origin > 38.5°C;
  • The third space effusion (including pleural effusion, abdominal effusion or pericardial effusion), poor clinical control or the need for local symptomatic treatment such as puncture and drainage;
  • Known impaired gastrointestinal (GI) function or known GI diseases that may significantly affect the absorption or metabolism of oral drugs.

Previous history of major surgery in the digestive tract (esophagus, gastrointestinal tract) that may alter the absorption or inability to swallow drugs in the study treatment;

  • Toxicity of previous antitumor therapy, except alopecia, pigmentation, clinically insignificant laboratory abnormalities) has not recovered to grade 1, and peripheral nerve toxicity has not recovered to grade 2 ( CTCAE v5.0);
  • Human immunodeficiency virus (HIV) antibody positive, liver cirrhosis or active viral hepatitis;
  • Active syphilis;
  • Patients with renal failure requiring hemodialysis or peritoneal dialysis;
  • Poor diabetes control [fasting blood glucose (FBG)> 10 mmol/L];
  • Previous history of organ transplantation or readiness to undergo organ transplantation;
  • Weight of <40 kg and BMI of <18.5 kg/m2, or weight loss of> 5% within 3 months before enrollment;
  • Major surgical treatment or significant traumatic injury within 4 weeks prior to the first dose of this study;
  • Receiving palliative radiotherapy with local lesions within 2 weeks before the first dose of this study;
  • Pregnant or lactating subjects;
  • With the combination of other primary malignancies
  • Serious mental or mental illness or history of substance abuse or serious alcohol abuse;
  • Known allergy to the investigational medicinal product or any ingredient in the formulation;
  • Any other significant clinical abnormality or disease that the investigator considers poses a risk to subject safety or interferes with the medication and evaluation of the clinical study.

Quoted from ClinicalTrials.gov, NCT06300177, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06300177, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06300177